SCHEMBL201018

SCHEMBL201018

COc1cccc(C(N)=O)c1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.50
LMNA P02545 2/20 0.50
KAT6A Q92794 1/20 0.50
IRAK4 Q9NWZ3 1/20 0.47
CTSD P07339 1/20 0.47
ADORA2A P29274 1/20 0.47
ADORA2B P29275 1/20 0.47
ADORA1 P30542 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
NPC1 O15118 3/20 0.46
PARP1 P09874 1/20 0.46
PARP14 Q460N5 1/20 0.46
PARP10 Q53GL7 1/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
CTNNB1 P35222 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10954882 0.85 KAT6A (0.52) HTTLMNAKAT6ACTSDSMN1; SMN2
SCHEMBL6118090 0.83 LMNA (0.44) HTTLMNASMN1; SMN2PARP14PARP10
SCHEMBL352148 0.83 HTT (0.58) HTTKAT6ASMN1; SMN2NPC1CA12
SCHEMBL7787275 0.83 SMN1; SMN2 (0.51) HTTLMNAKAT6ACTSDSMN1; SMN2
SCHEMBL2254189 0.81 KAT6A (0.54) LMNAKAT6ACTSDSMN1; SMN2NPC1
SCHEMBL27863827 0.81 KLK1 (0.44) HTTLMNAKAT6ACTSDSMN1; SMN2
Hydrochloric Acid SCHEMBL14157185 0.81 HTT (0.56) HTTKAT6ASMN1; SMN2NPC1CA12
SCHEMBL23137 0.81 KAT6A (0.50) HTTLMNAKAT6ACTSDSMN1; SMN2
SCHEMBL25248881 0.81 CTSD (0.70) LMNAKAT6ACTSDSMN1; SMN2NPC1
SCHEMBL28701340 0.80 KAT6A (0.47) HTTLMNAKAT6ACTSDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179008-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. (US) 2025-06-05 US disclosed
CN-119790057-A Novel PLK1 degradation inducing compounds 厄普特拉株式会社 2025-04-08 CN disclosed
US-20190307766-A1 CYCLIC AMINES MINDIMMUNE THERAPEUTICS, INC. 2019-10-10 US disclosed
US-10124010-B2 Cyclic amines MINDIMMUNE THERAPEUTICS, INC. (US) 2018-11-13 US disclosed
US-20180177793-A1 CYCLIC AMINES MINDIMMUNE THERAPEUTICS, INC. 2018-06-28 US disclosed
US-9861639-B2 Cyclic amines H. LUNDBECK A/S (DK) 2018-01-09 US disclosed
US-20170128460-A1 Cyclic Amines H. LUNDBECK A/S (DK) 2017-05-11 US disclosed
US-9593105-B2 Cyclic amines H. LUNDBECK A/S (DK) 2017-03-14 US disclosed
US-20170008898-A1 Cyclic Amines H. LUNDBECK A/S (DK) 2017-01-12 US disclosed
US-9415055-B2 Cyclic amines H. LUNDBECK A/S (DK) 2016-08-16 US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
EP-2074120-B1 TROPANE COMPOUNDS EXELIXIS INC (US) 2010-03-03 EP disclosed
US-20090137557-A1 Calcilytic Compounds SMITHKLINE BEECHAM CORPORATION 2009-05-28 US disclosed
US-20090137557-A1 Calcilytic Compounds SMITHKLINE BEECHAM CORPORATION 2009-05-28 US disclosed
CN-101404989-A Antibacterial agent PROLYSIS LTD (GB) 2009-04-08 CN disclosed
CN-101360498-A Calcilytic compounds SMITHKLINE BEECHAM CORP (US) 2009-02-04 CN disclosed
EP-1996180-A1 ANTIBACTERIAL AGENTS Prolysis Limited (GB) 2008-12-03 EP disclosed
EP-1951244-A2 CALCILYTIC COMPOUNDS SmithKline Beecham Corporation (US) 2008-08-06 EP disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 WO disclosed
WO-2007062370-A2 CALCILYTIC COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170008898-A1 Cyclic Amines P2RX7, ADORA2A, P2RX2 HTT 3695/4885LMNA 2464/4885KAT6A 3589/4885
US-20190307766-A1 CYCLIC AMINES P2RX7, ADORA2A, P2RX2 HTT 3695/4885LMNA 2464/4885KAT6A 3589/4885
US-20250179008-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 HTT 4286/4885LMNA 1817/4885KAT6A 2038/4885
US-20090137557-A1 Calcilytic Compounds CALCR, SOST, CALCB HTT 3362/4885LMNA 1316/4885KAT6A 4389/4885
US-20100173933-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 HTT 4286/4885LMNA 1817/4885KAT6A 2038/4885
US-10124010-B2 Cyclic amines P2RX7, ADORA2A, P2RX2 HTT 3695/4885LMNA 2464/4885KAT6A 3589/4885
US-20180177793-A1 CYCLIC AMINES P2RX7, ADORA2A, P2RX2 HTT 3695/4885LMNA 2464/4885KAT6A 3589/4885
US-20170128460-A1 Cyclic Amines P2RX7, ADORA2A, P2RX2 HTT 3695/4885LMNA 2464/4885KAT6A 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.